Introduction
The ageing process, like many other biological processes, is regulated by classical signaling pathways and transcription factors. Many of these pathways were first discovered in small, short-lived organisms such as yeast, worms and flies, but a remarkable fraction of these pathways turn out to extend lifespan in mammals as well (Kenyon 2010) . Lipoprotein metabolism, genomic instability, oxidative stress, cellular response to damage, inflammatory processes, TOR signaling, signals from the reproductive system, telomeres, insulin/IGF-1 A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT Vanhooren et al. Serum N-glycan biomarker 4 signaling and sirtuins have all been proposed as regulators of the ageing process (Whalley 2009 , Kenyon 2010 . For instance, DNA damage and repair plays a very important role in the ageing process. To avoid the deleterious consequences of genetic damage, the DNA of all organisms also encodes an intricate network of specialized DNA repair pathways. The vital importance of basic DNA repair mechanisms for maintaining genomic integrity is underscored by their extreme conservation from unicellular bacteria and yeast to man (Hoeijmakers 2001) . Defects in DNA repair systems either cause embryonic death or result in severe pathology later in life. Many patients and mouse mutants with defects in different nucleotide excision repair factors exhibit phenotypes reminiscent of premature ageing.
Defects in the transcription-coupled nucleotide excision repair factors CSA or CSB lead to Cockayne syndrome (CS) in humans (Mitchell 2003) .
After middle age, the body starts to experience a decline in various functions, and this leads to a high risk for ageing-associated diseases, such as cardiovascular disease, cancer, arthritis, cataract, osteoporosis, type 2 diabetes, hypertension and Alzheimer's disease. The incidence of all of these diseases increases rapidly with ageing. These age-related diseases can accelerate the ageing process. Dementia encompasses deteriorations in several cognitive domains (Morris, 2005) . It has been defined as a manifestation of deteriorating brain functions over time as a part of ageing due to death or functional decline of brain cells caused by neurodegeneration or other disease (Peng, 2003) . Alzheimer's disease (AD), the most common type of dementia, is a progressive, degenerative brain disease accounting for 65-70% of all dementia cases (Blennow et al., 2006) . The cause of AD is unknown, but ageing is one causative factor. The incidence of AD increases substantially after the age of 70 years and represents a major health concern and economic burden worldwide. Mutations that slow down ageing also postpone age-related diseases such as dementia (Kenyon 2010). Glycosylation is a form of co-translational and post-translational modification. Glycans serve a variety of structural and functional roles in membrane-bound and secreted proteins. An Nglycan (N-linked oligosaccharide) is a sugar chain covalently linked to an asparagine residue of a polypeptide chain. Analyses of protein sequence databases have revealed that about two thirds of those sequences are likely to be N-glycosylated (Varki A., 2009) . Glycans can mediate a wide variety of biological functions by virtue of their mass, shape, charge and other physical properties. Unlike protein sequences, which are primary gene products, glycan chain structures are not encoded directly in the genome but are secondary gene products. Glycans are synthesized in many different combinations by a variety of competing and sequentially acting glycosidases and glycosyltransferases without use of a template (Varki A., 2009) .
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Small alterations in the environment can cause dramatic changes in the glycans produced by a particular cell, and so N-glycosylation could mirror the status of the cell. We and others recently showed that the composition of serum N-glycans changes during human ageing (Knezevic et al., 2010; . Certain relatively specific alterations in the expression of glycans are also found during oncogenic transformation and progression to malignancy, as well as in other pathological conditions, such as inflammation (Kramer and Schulz-Schaeffer, 2007) . The spatial and temporal control of glycan expression implies the involvement of glycans in many physiological and pathological processes (Haltiwanger and Lowe, 2004; Ohtsubo and Marth, 2006) . Since N-glycosylation reflects in part the state of the cell, it could be a suitable biomarker not only for healthy ageing but also for age-related disease.
To determine whether changes in the extent and nature of posttranslational modification of proteins could be hallmarks of biological age, we investigated the N-glycosylation status of proteins in human blood. We also examined the serum N-glycosylation fingerprint in patients with age-related disease (dementia) and in patients suffering from Cockayne syndrome, a premature ageing syndrome caused by deficiency in a DNA repair. We defined a particular serum N-glycan profile shift during ageing as a biomarker.
Materials and methods
Serum samples from healthy Belgians
Serum samples from 425 healthy Belgian adults were obtained from the Biobank, Institute
Born-Bunge, and from the Transfusion Center of the Red Cross, Belgium, in accordance with Red Cross health standards. All of these people were in relatively good health and had no Vanhooren et al. Serum N-glycan biomarker 7 relevant acute or chronic disease affecting the immune system. They were divided in four age groups: 20-49 (n=60), 50-75 (n=160), 76-89 (n=30) and 90-99 years (n=175). Informed consent was obtained from all participants.
Serum samples from healthy Italians
Serum samples were obtained from 84 Italian centenarians . All were in relatively good health and had no relevant acute or chronic disease affecting the immune system. As controls, we studied three groups of healthy Italian volunteers of different ages: 20-49 (n=35), 50-75 (n=37) and 76-99 years (n=71). Informed consent was obtained from all participants.
Serum samples from dementia patients
Serum samples from 79 patients with autopsy-confirmed dementia were included. All sera samples were obtained from the Biobank, Institute Born-Bunge, Antwerp, Belgium. We . The study was approved by the local ethics committee (CME Middelheim Hospital, Antwerp).
Serum samples from patients with Cockayne Syndrome (CS)
Serum samples were obtained from six CS patients aged 3, 7, 8, 10, 10 and 20 years. N-glycan fingerprinting of all the samples was done as detailed before (Vanhooren et al., 2008) . N-glycan profiles were generated from 2-µl serum samples by DSA-FACE technology using a capillary electrophoresis (CE)-based ABI3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The intra-and inter-assay coefficients of variation (CV) of the glycan analyses are less than 5%.
Statistical analysis
All quantitative variables are presented as mean ± SD. The unpaired t-test was used for comparison of two groups, and for comparison of more than two groups, one-way ANOVA was performed. All reported P-values are two-tailed, and P-values < 0.05 are considered statistically significant. Statistical analysis was performed with SPSS15.0 software (SPSS, Chicago, IL, USA).
Results
The healthy human ageing biomarker GlycoAgeTest: shift of the serum glycoprofile
Our department developed an ultra-sensitive technique to quantitatively profile and sequence N-linked glycans using standard DNA-sequencing equipment (Laroy et al., 2006) , and we adapted this technique for the study of human ageing (Vanhooren et al., 2009) . Using "DNA Sequencer Adapted-Fluorophore Assisted Carbohydrate Electrophoresis" (DSA-FACE), an accurate fingerprint of the glycan composition in serum or plasma can be obtained.
The DSA-FACE procedure requires only 2 µl of serum and involves labeling of N-glycans, profiling, and read-out ( Fig. 1) . A typical N-glycan profile of human serum and plasma was previously generated and the nine most prominent structures corresponding to glycans in the profile were identified previously . The sizes of the peaks, which represent Using this approach, we previously performed a thorough study of the N-glycosylation status of serum proteins during ageing in 100 healthy Belgian blood donors (Belgian Red Cross, Ghent, Belgium) . The volunteers were from five age groups (20, 30, 40, 50 and 60 years) , each consisting of 10 males and 10 females. Several glycan structures were found to be closely related to ageing. In particular, peak 1 (an agalactosylated core-α-1,6-fucosylated biantennary; NGA2F) increased gradually with age, while peak 6 (a bigalactosylated, core-α-1,6-fucosylated biantennary; NA2F) decreased (Fig. 2) . The increases in peak 1 (agalacto-glycan, NGA2F) during ageing could be due to a greater abundance of beta-galactosidase, which removes two galactoses from Peak 6 (NA2F), or to a lesser abundance of beta-1,4-galactosyltransferase, which adds galactose to NGA2F (Fig 2) .
For precision and accuracy, a ratio of two variables is better than the use of a single measurement. In the current study, we defined the log ratio of NGA2F (peak1) and NA2F
(peak6) as a potential ageing biomarker, named GlycoAgeTest = log[NGA2F/NA2F] (log[P1/P6]). Using this formula, we reanalyzed its correlation with age in the Belgian volunteers. As shown in Figure 3 , the level of GlycoAgeTest remained steady until 40 years, and then increased. This observation demonstrates that the N-glycan profile is rather stable and consistent up to the age of 40 years. It starts to increase by the age of 50 and even more so after the age of 60 years. The intra-and inter-assay coefficients of variations (CVs) of the glycan analysis are less than 5%.
To see whether the shift in serum glycan profile is further increased at even higher later ages, we evaluated the GlycoAgeTest marker in 425 healthy Belgian volunteers in four age groups, including nonagenarians: 20-49 (n=60), 50-75 (n=160), 76-89 (n=30) and 90-99 (n=175).
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To see whether the GlycoAgeTest marker is also applicable to other populations, we tested a group of 229 healthy Italian volunteers (female n=160, male n=68) of different ages: 20-49 (n=35), 50-75 (n=37), 76-89 (n=33), 90-99 (n=39) and ≥100 years (n=84). The GlycoAgeTest displayed the same trend of change with age observed in the Belgian volunteers (Fig. 4) . This demonstrates that the alterations of glycan structures are closely related to the progress of human ageing at least in these two populations. Noteworthy, the level of GlycoAgeTest in the Italian volunteers was significantly lower (p<0.05) than in their age-matched Belgian.
GlycoAgeTest in patients with dementia and patients with Cockayne syndrome
We analyzed serum N-glycans by DSA-FACE in 79 Belgian patients with autopsy-confirmed dementia (31 of 50-75 years and 48 of 76-89 years). The GlycoAgeTest value was significantly higher (p<0.05) in dementia patients than in age-matched controls (Fig. 5 ), which suggests that the biological age of dementia patients corresponds to a higher chronological age.
On the other hand, progeroid syndromes can occur early in life and accelerate the ageing process, such as Cockayne syndrome (progeroid syndrome), which is a rare autosomal recessive disorder characterized by progressive multisystem degeneration and segmental premature ageing. The average reported life span of patients with CS is approximately 12.5 years (for extensive reviews on clinical characteristics of Cockayne syndrome: (Nance and Berry, 1992) (Licht et al., 2003) . Because many of the traits are reminiscent of normal ageing, CS has been classified as a segmental premature ageing syndrome.
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To analyze the sensitivity of the GlycoAgeTest for a segmental progeroid syndrome, we determined the serum glycan profile in six CS patients (age of 3 to 17 years). As shown in figure 6 , the level of GlycoAgeTest in the CS patients is highly heterogeneous, but even the lowest value is much higher than in the controls. The average score is in the same range as that of people in their nineties. Thus, even though the primary defect in CS is due to defective DNA damage repair, it appears that the profile of N-glycans in serum of these patients corresponds with dramatic accelerated ageing.
Discussion
We profiled serum N-glycans by using DSA-FACE to validate our serum N-glycan ageing biomarker, GlycoAgeTest, in different age groups of healthy human volunteers, patients with dementia, and patients with CS, a genetic disease involving progressive neurodysfunction and many features of premature ageing. We demonstrate that the GlycoAgeTest is better than chronological age at estimating the physiological age of human and that it could be used as a biomarker of healthy ageing in humans.
As we age, the functions and physiological reactions of our body gradually slow down, and this becomes apparent mainly after middle age. We found that the level of our GlycoAgeTest 
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ACCEPTED MANUSCRIPT Vanhooren et al. Serum N-glycan biomarker 12 This difference could be partly due to common lifestyle between Belgium and Italy, and genetic polymorphisms (Melzer, 2008; Agundez et al., 1997; Melzer et al., 2007) . It was recently documented that plasma N-glycans is affected by age, body mass index, plasma lipid profiles and smoking (Knezevic et al., 2010) . It is very interesting to further validate whether the GlycoAgeTest could identify accelerated ageing individual who is associated with lifestyle factors (such as smoking, obesity, lack of exercise and etc). The GlycoAgeTest is being validated further in 14 European nations in the context of the MARK-age project (www.mark-age.eu), a large-scale integrated project supported by the European Commission.
Moreover, we found that the GlycoAgeTest value was high in patients with dementia compared to age-matched healthy volunteers, which indicates that the biological age of dementia patients is higher than their chronological age. This was also observed in CS. The fact that a defect in the mechanisms of DNA damage repair, and particularly those dealing with DNA lesions that block transcription can lead to a dramatic alteration in the serum Nglycan profile is very interesting. This implies that indirect links exist between defective functioning of specific DNA repair processes and the synthesis or turn-over of specific carbohydrate chains in the ER and Golgi apparatus. In any case, the findings are consistent with the idea that CS is a (segmental) premature ageing syndrome and that DNA damage repair is fundamental to various cellular and organismal processes, including N-glycosylation.
The one common factor between between dementia and CS is the ageing process, and this common association provides a strong argument that our GlycoAgeTest measures a process related to the ageing process.
We previously showed that N-glycan markers can also clearly distinguish between the normal ageing process and disease because sugar structures are changed in different ways and to different extents. For instance, GlycoHCCTest and GlycoCirrhoTest are serum N-glycan diagnostic biomarkers for liver cancer and cirrhosis, respectively, and they were designed using different N-glycans from GlycoAgeTest (Callewaert et al., 2004; Liu et al., 2007) . As the changes in N-glycans are a consequence of genetic and environmental influences and physiologic responses, the GlycoAgeTest marker has a significant diagnostic potential. It could be used in combination with other existing ageing parameters: due to the intrinsic multicausal and multi-system nature of the ageing process, no single measurement has proven capable on its own of determining biological age (Barqawi et al., 2005; Johnson, 2006) .
The American National Institute of Ageing (NIA) has proposed the following requirements for a biomarker of ageing (Ward et al., 2006) . (1) It must predict the rate of ageing, i.e. it should determine how far one has progressed in his or her total life span, and it must predict this more accurately than chronological age.
(2) It must monitor a basic process that underlies the ageing process, not the effects of disease.
(3) Repeated testing should be harmless and should use, for example, a blood test or an imaging technique. (4) It should be possible to use it in humans and in laboratory animals, such as mice, so that it can be tested in lab animals before being validated in humans. Our GlycoAgeTest fulfills most of these criteria, and it is also extremely robust. Serum samples kept for years in the freezer yielded the same N-glycan profile even after numerous freeze-thaw cycles. Only 2 µl of serum is needed for generating the N-glycan profile, and so the marker can be easily repeated without harming the person.
Moreover, this marker has already been validated in mice (unpublished data).
The mechanism behind these age-related N-glycosylation alterations requires investigation.
Preliminary data indicate that the N-glycosylation changes are not limited to a certain serum protein but cover all serum glycoproteins. This need further study. Whether the Nglycosylation alterations are caused by differences in biosynthesis or clearance or by other factors is currently under investigation and should provide us with many interesting answers about the mechanism behind our GlycoAgeTest.
In summary, measuring the shift in serum N-glycan profile could be used to regularly evaluate the overall age-related health status. This not only facilitates the diagnosis of age-related diseases such as dementia, but also the follow-up of different therapies in individuals not suffering from accelerated ageing. As ageing is the biggest risk factor for all age-related diseases, which emerge mainly in middle age or later, detection of an abnormal N-glycan fingerprint and a faster-than-normal rate of ageing in a given individual would indicate the need for additional diagnostic and preventive measures. With a reliable GlycoAgeTest biomarker to predict biological age and monitor healthy ageing progress, it could become possible to take preventive measures to slow down ageing and age-related diseases. Arrow indicates the changed N-glycan or peak in old age. represents the 95% confidence interval for the mean of the percentage of total N-glycan peak height. The statistical significance of differences between groups is indicated by the p value. (n=30) and 76-99 years (n=53). These levels were compared to Belgian healthy controls: 20-49 (n=60), 50-75 (n=160), 76-89 (n=30), 90-99 (Belgian n=175). The GlycoAgeTest value was higher in the dementia patients than in age-matched healthy controls. The vertical axis represents the 95% confidence interval for the mean of the percentage of total N-glycan peak height. The statistical significance of differences between groups is indicated by the p value. 
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